| Literature DB >> 36078984 |
Keiji Sato1, Tatsuya Jujo1, Reio Sekine1, Naoto Uchiyama1, Kota Kakehashi1, Jiro Kogo1.
Abstract
We investigate-d whether biomarkers such as red blood cell hematocrit (Hct), platelet count (PLT), mean platelet volume (MPV), and platelet distribution width (PDW) are useful prognostic indicators of postoperative macular edema (ME) after vitrectomy for proliferative diabetic retinopathy (PDR). A total of 42 eyes of 42 patients with PDR who underwent vitrectomy between January 2018 and May 2020 were analyzed retrospectively. We divided them into two groups according to whether treatment was required for postoperative ME and compared the relationship between Hct, PLT, MPV, and PDW and the onset of postoperative ME. The group that received postoperative treatment (group T) comprised 11 eyes of 11 patients, and the group that did not (group N) comprised 31 eyes of 31 patients. The age (years) was 52.0 ± 3.1 in group T and 60.0 ± 11.6 in group N. When appropriate statistical analysis was performed for comparison between groups, significant differences were found in age (p = 0.05), insulin use (p = 0.03), preoperative intraocular pressure (p = 0.05), diastolic blood pressure (p = 0.03), and Hct (p = 0.04). Multivariate logistic regression analysis was performed, and a significant difference was found in Hct (p = 0.02). These results suggest that Hct might be useful as a predictor of ME after PDR surgery.Entities:
Keywords: diabetic macular edema; hematocrit; platelet volume index; proliferative diabetic retinopathy
Year: 2022 PMID: 36078984 PMCID: PMC9457308 DOI: 10.3390/jcm11175055
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Patient characteristics and baseline data.
| Characteristic | Group T | Group N | |
|---|---|---|---|
| No. of patients | 11 | 31 | |
| No. of eyes | 11 | 31 | |
| Sex (male/female) | 9/2 | 24/7 | 1.0 |
| Age (years; mean ± SD) | 52.0 ± 3.1 | 60.0 ± 11.6 | 0.05 |
| Hypertension, eyes (%) | 6 (54.6) | 26 (83.9) | 0.09 |
| Hyperlipidemia, eyes (%) | 4 (36.4) | 12 (38.7) | 1.0 |
| Oral hypoglycemic, eyes (%) | 6 (54.6) | 24 (77.4) | 0.24 |
| Oral metformin, eyes (%) | 4 (36.4) | 7 (22.6) | 0.44 |
| Insulin use, eyes (%) | 7 (63.6) | 8 (25.8) | 0.03 |
| Oral anticoagulant, eyes (%) | 1 (9.1) | 5 (16.1) | 1.0 |
| Oral antiplatelet, eyes (%) | 4 (36.4) | 7 (22.6) | 0.44 |
| Oral statin, eyes (%) | 5 (45.5) | 10 (32.3) | 0.48 |
| Oral diuretic, eyes (%) | 5 (45.5) | 16 (51.6) | 1.0 |
| Preoperative IOP (mmHg; mean ± SD) | 16.1 ± 3.1 | 13.6 ± 3.8 | 0.05 |
| Preoperative logMAR BCVA (mean ± SD) | 1.1 ± 0.7 | 1.1 ± 0.8 | 0.87 |
| Axial length (mm; mean ± SD) | 24.3 ± 1.5 | 24.1 ± 2.0 | 0.40 |
| Lens status; phakia/pseudophakia (eyes) | 8/3 | 22/9 | 1.0 |
| Surgical purpose, eyes | 11 | 31 | 0.41 |
| VH, eyes (%) | 6 (5) | 23 (74.2) | |
| RD, eyes (%) | 3 (27.3) | 3 (9.7) | |
| DME, eyes (%) | 1 (9.1) | 1 (3.2) | |
| Fibrovascular proliferation, eyes (%) | 1 (9.1) | 3 (9.7) | |
| Neovascularization elsewhere, eyes (%) | 0 (0) | 1 (3.2) | |
| Smoking, eyes (%) | 6 (54.6) | 20 (64.5) | 0.72 |
| Duration of smoking (years; mean ± SD) | 12.8 ± 9.6 | 14.6 ± 10.4 | 0.54 |
| BMI (kg/m2; mean ± SD) | 24.3 ± 2.9 | 27.0 ± 6.5 | 0.38 |
| Systolic blood pressure (mmHg; mean ± SD) | 131.6 ± 20.9 | 133.1 ± 17.8 | 0.82 |
| Diastolic blood pressure (mmHg; mean ± SD) | 69.4 ± 10.3 | 78.1 ± 10.9 | 0.03 |
| Pulse pressure (mmHg; ± SD) | 62.3 ± 20.0 | 55.0 ± 12.4 | 0.46 |
| Mean blood pressure (mmHg; mean ± SD) | 90.1 ± 10.5 | 96.4 ± 12.3 | 0.14 |
| Preoperative anti-VEGF vitreous injection, eyes (%) | 4 (36.4.2) | 6 (19.4) | 0.41 |
| Previous PRP, eyes (%) | 6 (54.6) | 21 (67.7) | 0.48 |
| Dialysis, eyes (%) | 3 (27.3) | 10 (65.7) | 1.0 |
| Preoperative DME, eyes (%) | 6 (54.6) | 7 (22.6) | 0.14 |
SD: standard deviation; IOP: intraocular pressure; logMAR: logarithm of the minimum angle of resolution; BCVA: best-corrected visual acuity; VH: vitreous hemorrhage; RD: retinal detachment; DME: diabetic macular edema; BMI: body mass index; VEGF: vascular endothelial growth factor; PRP: panretinal photocoagulation.
Comparisons of clinical characteristics between group T and group N.
| Characteristic | Group T | Group N | |
|---|---|---|---|
| HbA1c (%; mean ± SD) | 8.1 ± 2.2 | 6.8 ± 1.1 | 0.09 |
| Fasting blood glucose (mg/dL; mean ± SD) | 160.4 ± 89.3 | 136.4 ± 44.0 | 0.52 |
| PLT (103/µL; mean ± SD) | 235.9 ± 36.4 | 237.9 ± 65.4 | 0.92 |
| MPV (fl; mean ± SD) | 8.5 ± 1.1 | 8.2 ± 0.9 | 0.51 |
| PDW (fl; mean ± SD) | 16.9 ± 0.5 | 17.1 ± 0.5 | 0.43 |
| Hct (%; mean ± SD) | 42.0 ± 5.6 | 37.6 ± 5.6 | 0.04 |
| LDL (mg/dL; mean ± SD) | 134.8 ± 52.7 | 101.1 ± 42.3 | 0.06 |
| HDL (mg/dL; mean ± SD) | 54.0 ± 9.3 | 51.1 ± 18.4 | 0.26 |
| TG (mg/dL; mean ± SD) | 148.9± 111.0 | 150.7 ± 129.4 | 0.89 |
| eGFR (mL/min/1.73 m2; mean ± SD) | 42.8 ± 21.7 | 46.1 ± 57.7 | 0.68 |
| Hb (g/dL; mean ± SD) | 13.7 ± 2.0 | 12.6 ± 2.2 | 0.12 |
| Cr (mg/dL; mean ± SD) | 2.6 ± 3.2 | 3.0 ± 2.7 | 0.51 |
| BUN/Cr ratio (mean ± SD) | 14.5 ± 6.9 | 16.1 ± 8.7 | 0.71 |
| BUN (mg/dL; mean ± SD) | 26.7 ± 22.2 | 31.4 ± 16.1 | 0.06 |
SD: standard deviation; HbA1c: hemoglobin A1c; PLT: platelet count; MPW: mean platelet volume; PDW: platelet distribution width; Hct: hematocrit; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; TG: triglyceride; eGFR: estimated glomerular filtration rate; Hb: hemoglobin; Cr: creatinine value; BUN: blood urea nitrogen.
Postoperative clinical data.
| Characteristic | Group T | Group N | |
|---|---|---|---|
| Cataract surgery, eyes (%) | 7 (63.6) | 18 (58.1) | 1.0 |
| ILM peeling, eyes (%) | 8 (72.7) | 22 (71.0) | 1.0 |
| Gas tamponade, eyes (%) | 2 (18.2) | 8 (25.8) | 0.84 |
| Air, eyes (%) | 1 (9.1) | 3 (9.7) | |
| SF6, eyes (%) | 1 (9.1) | 5 (16.1) | |
| C3F8, eyes (%) | 0 (0) | 0 (0) | |
| Postoperative logMAR BCVA (mean ± SD) | |||
| 1 month | 0.49 ± 0.43 | 0.51 ± 0.53 | 0.90 |
| 3 months | 0.38 ± 0.35 | 0.36 ± 0.36 | 0.80 |
| 6 months | 0.18 ± 0.18 | 0.31 ± 0.38 | 0.76 |
| 12 months | 0.02 ± 0.07 | 0.18 ± 0.29 | 0.43 |
| Postoperative IOP (mmHg; mean ± SD) | |||
| 1 month | 15.2 ± 4.7 | 14.9 ± 5.1 | 0.78 |
| 3 months | 14.3 ± 4.3 | 14.7 ± 4.9 | 0.81 |
| 6 months | 17.7 ± 5.3 | 13.8 ± 3.7 | 0.03 |
| 12 months | 16.4 ± 3.8 | 13.8 ± 3.0 | 0.11 |
| Follow-up period (months; mean ± SD) | 7.6 ± 4.3 | 9.3 ± 3.6 | 0.21 |
ILM: internal limiting membrane; SF6: sulfur hexafluoride; C3F8: octafluoropropane; logMAR: logarithm of the minimum angle of resolution; BCVA: best-corrected visual acuity; SD: standard deviation; IOP: intraocular pressure.
Multivariate logistic regression analyses of risk factors associated with PVI.
| Analysis ( | Factor | Odds Ratio (95% CI) | |
|---|---|---|---|
| Multivariate logistic regression | PLT (103/µL) | 1.00 (0.99–1.02) | 0.66 |
| MPV (fl) | 0.38 (0.13–1.16) | 0.09 | |
| PDW (fl) | 7.41 (0.80–68.6) | 0.08 | |
| Oral statin, eyes (%) | 1.20 (0.25–5.73) | 0.82 | |
| Oral metformin, eyes (%) | 2.34 (0.46–11.8) | 0.30 |
PVI: platelet volume index; CI: confidence interval; PLT: platelet count; MPW: mean platelet volume; PDW: platelet distribution width.
Multivariate logistic regression analyses of risk factors associated with Hct.
| Analysis ( | Factor | Odds Ratio (95% CI) | |
|---|---|---|---|
| Multivariate logistic regression | Hct (%) | 0.84 (0.72–0.98) | 0.02 |
| BUN/Cr ratio | 1.08 (0.97–1.21) | 0.19 |
Hct: hematocrit; CI: confidence interval; BUN: blood urea nitrogen; Cr: creatinine.
Figure 1ROC curve of Hct.